Effect of Vitamin D3 Supplementation on Symptomatic Uterine Fibroid in Women With Vitamin D Deficiency

Effects of vitamin D supplimentation on symptomatic uterine fibroid will be checked

Inclusion criteria

.Women aged between 18-50 not currently pregnant, lactating, or planning to conceive during the study period.

• Women with a confirmed diagnosis of uterine fibroids (leiomyoma) through ultrasound.
• Serum 25-hydroxyvitamin D [25(OH)D] levels below 20 ng/mL (indicating vitamin D deficiency).
• Presence of symptoms associated with uterine fibroid, such as menorrhagia (heavy menstrual bleeding), or bulk-related symptoms (e.g., urinary frequency).
• Participants should be generally healthy, with no history of other chronic illnesses that could affect the study's outcomes (e.g., autoimmune diseases, cancers, severe liver or kidney diseases).
• Willingness to provide written informed consent for participation in the study.
• No current use of hormonal therapy, other vitamin D supplements, or medications known to influence calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens).
• Participants must be willing and able to adhere to the study protocol, including attending follow-up visits and completing any required assessments or tests.

Exclusion criteria

• Women younger than 18 or older than 50 years.
• Serum 25-hydroxyvitamin D [25(OH)D] levels of 20 ng/mL or higher.
• Women without a confirmed diagnosis of uterine fibroids (leiomyoma) through imaging.
• Pregnant or breastfeeding women, or those planning to conceive during the study period.
• Presence of chronic illnesses such as autoimmune diseases, cancers, or severe liver or kidney disease that could interfere with the study's outcomes.
• Current or recent use of hormonal therapy, other vitamin D supplements, or medications that affect calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens).
• Women who have undergone surgical interventions (e.g., myomectomy, hysterectomy) or other medical treatments specifically for uterine fibroid within the past 6 months.
• Women with conditions like hyperparathyroidism or calcium disorders that might affect vitamin D metabolism or fibroid growth.